MediWound to Present New Data from EscharEx Phase II Studies at Three Leading Wound Care Conferences

Oral presentations include additional comparative data between EscharEx and SANTYL, and new analyses show strong correlation between wound bed preparation and wound healing

Analyses validate the planned design and endpoints of the upcoming Phase III study

YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).

The oral presentations on EscharEx will include:

• Comparative data of EscharEx vs. SANTYL that demonstrate EscharEx’s superiority over the current leading enzymatic debridement agent
• New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing

These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care. Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024.

"We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL, the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound. "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."

2024 European Wound Management Association (EWMA), London, United Kingdom
Time:	May 1, at 11:45am
Title:	Comparison of bromelain-based enzymatic debridement to collagenase ointment
Presenter:	Cyaandi R. Dove, DPM
Time:	May 3, at 8:30am
Title:	VLU wound bed preparation is highly correlated with wound closure
Presenter:	Robert J. Snyder, DPM, MSc, MBA
2024 Wound Healing Society Conference (WHS), Orlando, Florida
Time:	May 16, at 10:30am
Title:	Comparison of bromelain-based enzymatic debridement to collagenase SANTYL ointment
Presenter:	Cyaandi R. Dove, DPM
Time:	May 16, at 10:30am
Title:	VLU wound bed preparation is highly correlated with wound closure
Presenter:	Marissa Carter, MA, PhD
2024 Symposium on Advanced Wound Care (SAWC), Orlando, Florida
Time:	May 17, at 7:30am
Location:	SAWC Innovation Theater
Title:	EscharEx, an innovative multimodal enzymatic debridement agent for the treatment of chronic wounds
Presenters:	Vickie R. Driver, DPM, MS, FACFAS, John C. Lantis, MD, Cyaandi R. Dove, DPM, and Robert J. Snyder, DPM, will discuss the importance of wound bed preparation in wound healing, EscharEx’s mechanism of action, results from the ChronEx Phase II study including case studies showcasing the treatment experience, and the design of the upcoming Phase III study in venous leg ulcers (VLU)

About EscharEx